Vyvron Review: 13 Charges a Year, Not 12

Vyvron is new. It says so itself, more honestly than most new companies do: its testimonial section ships with placeholder text explaining that patient stories will appear once founding members have given written consent. There is no track record here, and the company is not pretending there is one.

What it does have is a pricing table with two problems, and both of them make the product cost more than the page says.

The unit is not a month

Vyvron's own fine print reads $199 per four weeks, billed every four weeks, auto-renewing until you cancel. Elsewhere on the same site, in the same bundle of code, the same plan is rendered as "from $199/mo" and "starting at $199/mo".¹

A four-week cycle is not a month. Fifty-two weeks divided by four is thirteen charges a year, not twelve. At the $199 rung that is $2,587 over a year rather than the $2,388 the "/mo" label implies — a difference of one full charge that no page on the site ever states. Nothing about that is unlawful, and it is not even hidden: the disclosure exists, it is simply in a different place from the number. That is exactly the kind of gap our true-cost calculator exists to close, and exactly the kind of thing that how we grade a provider treats as a price-honesty fault rather than a rounding error.

You cannot buy Vyvron's tirzepatide by the month

This is the finding that decides the review. Vyvron's weight-loss page shows three tiers, and only one of them is a recurring plan.

Start is $199 per four weeks, billed every four weeks. It is semaglutide only, and it is the only ongoing rung on the site.

Transform, badged as the most popular option, displays $285/mo. It is not a monthly plan. It is $790 billed once for twelve weeks of tirzepatide.

Premium displays $248/mo. It is $2,981 billed once for a full year of tirzepatide.

So the cheapest way into tirzepatide at Vyvron is $790 up front, and there is no monthly tirzepatide rate to quote because none exists. We are not going to fill that gap with a prepay figure divided by something — that substitution is how a provider with no monthly option ends up looking cheap on a cost board. Our tirzepatide ruling prints monthly prices, and Vyvron has none to print.

It is worth looking at the arithmetic behind that "$285/mo" too. $790 across twelve weeks is $285 if you divide by about 2.77 calendar months, and $263 if you divide by three four-week cycles. Vyvron uses four-week cycles for billing and calendar months for display, which means two different definitions of "per month" are running inside one pricing table.

Founding rates, and where they disagree with themselves

The three programs are priced as founding-member rates: weight loss at $199 per four weeks against a list rate of $249, microdosing at $149 against $179, and longevity at $189 against $229.¹ Within the longevity program, injectable NAD+ is $229 a month, injectable sermorelin $229, and injectable B12-MIC $145.²

The homepage cards tell a different story. They show microdosing at $179 — which is the post-founding list price, presented as the current one — and longevity at $145, which is the cheapest single item in the programme rather than the programme rate. The program pages are where the enrolment button and the billing disclosure live, so those are the ones we treat as governing. If you saw a number on the homepage and a different one on the page you enrolled from, the second one is the real one.

And the urgency device is not real. "100 of 100 founding spots left" is driven by a hardcoded constant with a progress bar fixed at full width. It has never counted down and it never will.

What Vyvron gets right

Two things, and both are substantial.

The clinical layer is OpenLoop Health, Inc. and its affiliated professional entities — a real, established telehealth infrastructure company rather than a name invented for the site. That is the strongest single fact about this provider.

And the state disclosure is the best of the seven providers we screened. Vyvron serves all 50 states and the District of Columbia, names the eight jurisdictions where a video visit is required rather than an asynchronous one — Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia — and states outright that compounded GLP-1 is not available in Mississippi at all. Most companies in this market will not tell you which states they serve; this one tells you which states change the process. That deserves saying, and it is the level of specificity our provider checklist asks for and rarely gets.

What it does not tell you, and what it charges you first

No pharmacy is named — you get "a licensed pharmacy". No prescriber is named and no NPI is published, so nobody here can be checked against the national registry. The legal entity is Vyvron, LLC, registered at an address in Sheridan, Wyoming that is the most heavily used registered-agent mail drop in the United States. That is not evidence of anything on its own; it is simply not evidence of an operating business either.

You are charged when you complete the intake form, before a provider reviews you. A full refund is available only if you cancel within 72 hours with no services rendered, or if a provider medically disqualifies you. Cancelling a recurring plan requires 72 hours' notice before the next billing date or you are charged for that cycle. On the prepaid Transform and Premium plans, refunds cover only the months whose medication has not shipped — which, on a $2,981 annual plan, is a term worth reading twice before you pay it.

We screened Vyvron and its clinical partner against the FDA's live warning-letter index and found no company-column match.³ The pass carried a control — an unrelated telehealth seller with a real February 2026 letter — which returned correctly, so that zero is a result rather than a broken query.

The ruling

Vyvron's semaglutide rung is fair and its clinical backing is real, so if you want compounded semaglutide and you are comfortable being an early customer, $199 every four weeks is a defensible buy as long as you budget thirteen of those charges a year rather than twelve. Its tirzepatide is a different product entirely: $790 before you have taken a single dose, with no monthly alternative. Anyone who wants tirzepatide on a month-to-month basis should be reading Auren Rx at $299 or The Edit at $309 instead, and comparing them on our board of verdicts rather than on a founding-rate banner.